FDA Approves HLB's FGFR2 Inhibitor Lificty for Previously Treated FGFR2-Fusion Cholangiocarcinoma
核心洞察
The FDA approved lirafugratinib, marketed as Lificty (搜索) or Lypiktu (搜索), for adults with unresectable locally advanced or metastatic FGFR2 (搜索) fusion-positive cholangiocarcinoma (搜索) after prior treatment.
Approval was based on the global Phase 1/2 ReFocus trial, which showed an objective response rate of about 46% and a median duration of response of 11.8 months.
Elevar Therapeutics (搜索), HLB (搜索)'s U.S. subsidiary, plans a U.S. launch in the fourth quarter of 2026 and filed an EMA marketing authorization application in September.
The U.S. Food and Drug Administration has approved lirafugratinib, an oral FGFR2 (搜索)-selective targeted therapy, for adults with unresectable locally advanced or metastatic cholangiocarcinoma (搜索) whose tumors carry a fibroblast growth factor receptor 2 (FGFR2) gene fusion or rearrangement and who have received prior treatment. HLB (搜索)'s U.S. subsidiary Elevar Therapeutics (搜索) announced the approval on September 24, Korean time, saying it was granted a day earlier.
The drug is marketed as Lificty (搜索) in one company announcement and Lypiktu (搜索) in another, with lirafugratinib as the generic name. Elevar plans to launch it in the United States in the fourth quarter of this year.
Regulatory first for a South Korean company
According to HLB (搜索), this is the first case in which a domestic pharmaceutical or biotech company directly submitted a new drug application for an anticancer drug, holding global rights, to the FDA and received approval. Elevar led the regulatory process after acquiring global development and commercialization rights to lirafugratinib from U.S.-based Relay Therapeutics in December 2024, when the drug was in Phase 1/2 trials.
Mechanism and selectivity
Lificty (搜索) is an oral targeted therapy that selectively inhibits FGFR2 (搜索), which the company describes as a key player in cancer initiation and progression. It is designed to bind FGFR2 irreversibly for sustained inhibition while minimizing inhibition of other FGFR subtypes, FGFR1, FGFR3 and FGFR4, an approach intended to reduce side effects caused by hitting receptors outside the target.
ReFocus trial results
The approval was based primarily on the global Phase 1/2 ReFocus trial, which enrolled 116 patients with cholangiocarcinoma (搜索) who had not previously received an FGFR inhibitor following prior chemotherapy or chemoimmunotherapy. According to the FDA, the objective response rate was 46%, and the median duration of response was 11.8 months. A second report of the same data put the objective response rate among patients in the approved group at 45.7%, with a median duration of response of 11.8 months among responders.
Commercial and clinical context
Bile duct cancer is diagnosed in about 8,000 people in the United States each year, according to the American Cancer Society. Market researcher Fortune Business Insights estimates the total U.S. bile duct cancer treatment market at about $540 million as of 2026, a figure covering both intrahepatic and extrahepatic disease. The National Cancer Institute says FGFR2 (搜索) gene fusions appear in about 15% of intrahepatic cases, so the treatable population is smaller than the overall patient pool. Existing FGFR-targeting drugs are already approved, and how Lypiktu (搜索) compares with those treatments is seen as a variable in its commercialization.
"The FDA approval of Lificty (搜索) is significant in providing an important second-line treatment option for patients with cholangiocarcinoma (搜索) and their families," said Dongkeun Kim, chief executive of Elevar. "We will do our best to ensure that Lificty is supplied as quickly as possible to healthcare professionals and patients, and to improve the treatment environment for patients whose treatment options have been limited."
European filing and broader development
Elevar submitted a marketing authorization application to the European Medicines Agency (搜索) on September 14, starting the European approval process. Trials are also underway in patients with other solid tumors carrying FGFR2 (搜索) gene fusions or rearrangements.